Transforming the Future of Life Sciences Through Dassault Systèmes

The transformative power of collaboration is no better illustrated than in life sciences. By sharing vital data, insights, and discoveries, we can power leaps and bounds in healthcare that improve and save lives every day.

The life sciences industry is at an inflection point. The transformative power of artificial intelligence (AI) and machine learning to deliver new treatments is tempered by the increasing cost and complexity of clinical trials, as well as the need to keep up with the ever-evolving regulatory landscape. Our customers are dealing with greater pressure than ever before to be fast, efficient and cost-effective, all while mitigating risk and ensuring quality throughout the clinical research lifecycle.

We came together with Dassault Systèmes (3DS) five years ago to tackle these challenges, by bringing transformational value to the market through a connected ecosystem of best-in-class clinical research solutions. As part of 3DS Life Sciences, we joined a greater whole servicing the life sciences industry, with the technology to revolutionize healthcare through cutting-edge innovations and insights. This empowers our customers to combat the challenges they face by delivering a 360-degree, end-to-end approach—from discovery to commercialization and beyond.

In 2023, 65% of novel drugs approved by the FDA were supported by 3DS Life Sciences platform solutions.

3DS Life Sciences is collaborating with customers like never before to accelerate new therapies and improve patients’ lives. We can arm them with the tools they need to illuminate insights for more strategic investment decision-making, identify and mitigate risk before it happens, and ensure acceleration and speed to market.

“With Dassault Systèmes Life Sciences, customers simplify a large portion of their ecosystem and we can solve things faster together.” 

–Tom Doyle, SVP, Chief Technology Officer, Medidata

In addition, we can greatly reduce the risk to patients through our virtual twin technology. Employing advanced modeling, analytics, and AI technologies from across the 3DS Life Sciences portfolio, we can generate a 3D simulation of a human body. This enables researchers to visualize hidden structures such as internal organs, tissues, and DNA, and to test the efficacy of treatments virtually.

And it’s not just the human body—virtual twins can visualize any object, system, or process, enabling massive strides in efficiency and innovation for product development, manufacturing and sustainability that are transforming the world as we know it.

As an example, 3DS Life Sciences is collaborating with numerous customers to accelerate their cell and gene therapy (CGT) development, regulatory approval, manufacturing, and supply chain in a global landscape by leveraging an extensive, connected, and comprehensive platform. 3DS Life Sciences enables companies to address each of the challenges associated with bringing CGTs to the market—from concept to patient—satisfying unmet medical needs and allowing patient access to the right treatment at the right time. This case study details CGT challenges and how we can help customers to address them.

With the Living Heart Project, our virtual modeling and AI technologies are increasing patient safety through medtech in-silico clinical trials. This ethical alternative to traditional testing leverages computational modeling simulation to create personalized, highly accurate digital human heart models. These trials expedite time-to-market, increase patient safety, and are more cost effective, delivering an invaluable new tool in drug and medical device development.

We stand at the dawn of a new era for Medidata. As part of 3DS Life Sciences, we can leverage unprecedented resources and expertise to further expand our mission to uncover smarter treatments that profoundly improve patient lives with our customers worldwide.

We’re excited to share this pivotal moment with you.

Learn more about how we’re driving the future of life sciences innovation.